| Name | Title | Contact Details |
|---|
Our name, Aptuit, is derived from the words aptitude and intuition, two natural attributes that define our unique approach to providing drug discovery, development and manufacturing support. The name communicates our aptitude for scientific knowledge as well as our intuitive understanding of the needs of the pharmaceutical and biotechnological community. We summon these attributes to clarify current challenges and anticipate those that are to come, always with the determination to find solutions. Since Aptuit was founded in 2004, we have forged a robust expansion of our resources. We are living up to the promise of our name by the ongoing assembly of experienced and talented scientists, and we are supporting them every step of the way with the most advanced resources at state-of-the art facilities. Our corporate tagline - Uncommon Expertise. Exceptional Results - reflects our success in harnessing unique and outstanding strengths in drug discovery and drug development to deliver the results that our clients demand.
Higher Dimension Research is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers.
We believe that our Hypermatrix technology is a novel and robust controlled-release drug delivery platform. This unique technology allows us to provide life-cycle management or new chemical entity delivery system solutions for virtually any small molecule. The flexibility of this technology allows us to quickly develop complex drug delivery solutions.
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).